Show simple item record

dc.contributor.authorHasan, Irtiza et al.
dc.date.accessioned2021-01-11T16:41:33Z
dc.date.available2021-01-11T16:41:33Z
dc.date.issued2020-11-05
dc.identifier.urihttps://doi.org/10.2478/rjim-2020-0034en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12663/2474
dc.description.abstractIntroduction: COVID-19 presents a special challenge to the kidney transplant population. Methods: A systematic review of articles that examined COVID-19 in kidney transplant recipients was performed. Patients' demographics, clinical, laboratory and radiological presentations, immunosuppression modification, and COVID-19 specific management were abstracted and analyzed. COVID-19 severity was classified into mild, moderate, and severe. Disease outcome was classified by whether the patient was discharged, still hospitalized, or died. Results: 44 articles reporting individual data and 13 articles reporting aggregated data on 149 and 561 kidney transplant recipients respectively with COVID-19 from Asia, Europe and America fulfilled all inclusion and exclusion criteria. Among studies reporting case specific data, 76% of cases had severe disease. Compared to patients with mild/moderate disease, patients with severe disease had higher CRP, LDH, Ferritin, D-dimer and were more likely to have bilateral lung involvement at presentation and longer time since transplantation (P<0.05 for all). Recipients' age, gender and comorbidities did not impact disease severity. Patients with severe disease had a more aggressive CNI reduction and more antiviral medications utilization. Outcome was reported on 145 cases, of those 34 (23%) died all with severe disease. Longer duration from transplant to disease diagnosis, hypoxia and higher LDH were associated with mortality (P<0.05). Different immunosuppression reduction strategies, high dose parenteral corticosteroids use and various antiviral combinations did not demonstrate survival advantage. Similar finding was observed for studies reporting aggregated data. Conclusion: COVID-19 in kidney transplant patients is associated with high rate of disease severity and fatality. Higher LDH and longer time since transplantation predicted both disease severity and mortality. None of the COVID-19 specific treatment correlated with, or improved disease outcome in kidney transplant recipients.en_US
dc.languageEnglishen_US
dc.subjectCOVID-19en_US
dc.subjectCoronavirus Infectionsen_US
dc.subjectCoronavirusen_US
dc.subjectInfectious Diseasesen_US
dc.subjectBetacoronavirusen_US
dc.subjectPandemicsen_US
dc.subjectImmunosuppressionen_US
dc.subjectTransplantsen_US
dc.subjectSARS-CoV-2en_US
dc.subjectTransplant Recipientsen_US
dc.subjectAcute Kidney Injuryen_US
dc.titlePredictors of disease severity and outcome of hospitalized renal transplant recipients with COVID-19 infection: A systematic review of a globally representative sampleen_US
eihealth.countryOthersen_US
eihealth.categoryClinical characterization and managementen_US
eihealth.typePublished Articleen_US
eihealth.maincategorySave Lives / Salvar Vidasen_US
dc.relation.ispartofjournalRomanian Journal of Internal Medicineen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record